- Trial Phase
- Approved
- Time to Market
- Already approved and marketed — initial US approval was 2005; no approval timeline applies. Remaining question is how fast generic share grows after volume caps ended Jan 31, 2026.
- Why 3/10
- No hard, dated binary for Revlimid in the next ~12 months — it is already approved (US initial approval 2005) and its defining catalysts (first generic launch March 2022; generic volume caps ending Jan 31, 2026) have passed — so the only "events" are quarterly revenue prints showing continued erosion, capping the score at 3 for a declining legacy line inside a ~$129B company.
For BMY shareholders, Revlimid is no longer a stock-moving binary — Q2 2026 sales fell ~49% YoY on generic erosion and full-year guidance was raised anyway, so the thesis now lives in the Growth Portfolio. Watch the quarterly earnings prints for the pace of post-volume-cap erosion, and note that the actual multiple-myeloma franchise catalysts are BMS's separate drugs iberdomide (PDUFA Aug 17, 2026) and mezigdomide (PDUFA May 13, 2027) — not Revlimid.
Price Chart
Executive Summary
Revlimid (lenalidomide) is the Celgene blockbuster that became a Bristol Myers Squibb product in the 2019 acquisition; first approved in the US in 2005, it peaked near $12.8B in 2021. US exclusivity is gone: the first generic arrived March 2022 and the last volume caps on generic supply ended Jan 31, 2026, unleashing full price competition (Accord launched Feb 2026). BMS's Q2 2026 earnings showed Revlimid down ~49% YoY — but the company beat estimates and raised guidance on its Growth Portfolio, so Revlimid is now a melting legacy asset rather than a thesis-driver. No regulatory or clinical catalyst for Revlimid is pending.
How It Works
An oral "immunomodulatory" drug — it re-tunes the body's immune response and acts directly on blood-cancer cells — used mainly for multiple myeloma, myelodysplastic syndromes (MDS) and certain lymphomas. Because it can cause severe birth defects, it is dispensed only through a restricted REMS program.
Trial Status
Commercial-stage; not in registrational trials. Local trial data shows only completed Phase 2 combination studies (e.g., NCT01241734, NCT01572480) — no pending readouts for Revlimid itself. The commercial battle is now generic entry: first generic launched March 2022, and volume restrictions on generics ended Jan 31, 2026, with Accord launching Feb 2026.
The Two-Sided Case
Upcoming Catalysts
- Q3 2026 earnings (approx. late Oct 2026): Revlimid erosion pace and any further generic-share gains — the only regular Revlimid-specific datapoint.
- Ongoing unrestricted generic competition post-Jan 31, 2026 — watch price/volume dynamics rather than a single event.
- Context only, NOT Revlimid: BMS multiple-myeloma pipeline PDUFAs for iberdomide (Aug 17, 2026) and mezigdomide (May 13, 2027) are the real MM-franchise catalysts for the stock.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BRISTOL MYERS SQUIBB CO 8-K BMY ·Originating report